P106 Evaluation of the safety and efficacy of the Derivo 2Heal® flow diverter under standard or reduced-dose single antiplatelet therapy

<h3>Introduction</h3> Flow diverter devices with surface modification or coating have been presented to the market in order to decrease the potential thrombogenicity of the devices and they are supposed to reduce the rate of thromboembolic complication during endovascular treatment. <h3>Aim of Study</h3> To evaluate the results of the Derivo2Heal® device (D2H), a new fibrin- and heparin-coated flow diverter <h3>Methods</h3> Patients treated with D2H were retrospectively evaluated for demographic data, aneurysm characteristics, procedural variables and follow-up data. All patients were treated using a single D2H, monitored by platelet function testing and kept under single antiplatelet therapy with regular or half-dose clopidogrel or prasugrel after the procedure. <h3>Results</h3> Thirty-three patients with 40 aneurysms were treated. Three presented acutely with subarachnoid hemorrhage. There were no technical failures. During follow-up, one of the acutely ruptured aneurysms reruptured, one patient had a visual TIA, one patient had parent artery thrombosis but remained asymptomatic. All patients were doing well clinically with 1 patient having an mRs of 1 at the last follow-up. The rates of total occlusion on very early angiographic (MRA/CTA or DSA, mean:2.4 months), and mid-term angiographic (mean:11.5 months) follow-up for all aneurysms were 67.6% and 90.9%, respectively. <h3>Conclusion</h3> The D2H stent with novel coating comprising fibrin and heparin seem to be a safe and efficient device with promising results however further studies comparing the D2H device with its bare counterpart as well as other coated or surface modified flow diverters are needed.